Cancer Treatment Reviews
Volume 25, Issue 1 , Pages 47-58 , February 1999

Cisplatin and hypomagnesemia

References 

    REFERENCES
  1. Quamme GA. Control of magnesium transport in the thick ascending limb. Am J Physiol. 1989;256:F197–F210
  2. Elin RJ. Overview of problems in the assessment of magnesium status. Magnesium in cellular processes and medicine. Basel: Karger; 1987; p. 67–76
  3. McLean RM. Magnesium and Its Therapeutic Uses: A Review. Am J Med. 1994;96:63–76
  4. Quamme GA. Renal magnesium handling: New insights in understanding old problems. Kidney Int. 1997;52:1180–1195
  5. Wacker WEC and Parisi AF. Magnesium metabolism. N Engl J Med. 1968;278:658–663, 712–717, 772–776
  6. Kjeldsen K, Nørgaard Aa. Effect of Magnesium depletion on3. Magnesium. 1987;6:55–60
  7. Dørup I, Skajaa K and Clausen T. A simple and rapid method for the determination of the concentrations of magnesium, sodium, potassium and sodium, potassium pumps in human skeletal muscle. Clin Sci. 1988;74:241–248
  8. Dørup I, Skajaa K, Clausen T and Kjeldsen K. Reduced concentrations of potassium, magnesium, and sodium-potassium pumps in human skeletal muscle during treatment with diuretics. Br Med J. 1988;296:455–458
  9. Reinhart RA. Clinical corelates of the nolecular and cellular actions of magnesium on the cardiovascular system. Am Heart J. 1991;121:1513–1521
  10. Robeson BL, Maddox TL and Martin WG. Muscle Changes in rats Fed Magnesium and Calcium Deficient Diets. J Nutr. 1979;109:1383–1389
  11. Hickie RA, Wei JW, Blyth LM, Wong DY and Klaassen DJ. Cations and calmodulin in normal and neoplastic cell growth regulation. Can J Biochem Cell Biol. 1983;61:934–941
  12. Mildvan AS and Loeb LA. The role of metal ions in the mechanisms of DNA and RNA polymerases. CRC Crit Rev Biochem. 1979;6(3):219–244
  13. Kimura T, Yasue H, Sakaino N Rokutanda M, Jougasaki M and Araki H. Effects of magnesium on the tone of isolated human coronary arteries. Circulation. 1989;79:1118–1124
  14. Nadler JL, Goodson S and Rude RK. Evidence that prostacyclin mediates the vascular action of magnesium in humans. Hypertension. 1987;9:379–383
  15. Requena J and Mullins LJ. Calcium movement in nerve fibres. Q Rev Biophys. 1979;12:371–460
  16. Orlov MV, Brodsky MA and Douban S. A Review of Magnesium, Acute Myocardial Infarction and Arrhytmia. J Am Coll Nutr. 1994;13(2):127–132
  17. Fine KD, Santa Ana CA and Porter JL. Intestinal absorption of magnesium from food supplements. J Clin Invest. 1991;88:396
  18. Quamme GA. Laboratory Evaluation of Magnesium Status. Clin Lab Med. 1993;13(1):209–223
  19. Elin RJ. Assessment of Magnesium Status. Clin Chem. 1987;33(11):1965–1970
  20. Bell DR, Woods RL and Levi JA. Cis-diamminedichloroplatinum-induced Hypomagnesemia and Renal Magnesium Wasting. Eur J Cancer Clin Oncol. 1985;21:287–290
  21. Speich M, Bousquet B and Nicolas G. Reference values for ionized, complexed and protein-bound plasma magnesium in men and women. Clin Chem. 1981;27:246–248
  22. Walser M. Magnesium metabolism. Rev Physiol biochem Exp Pharmacol. 1967;59:185–341
  23. Kroll MH and elin RJ. Relationships between magnesium and protein concentrations in serum. Clin Chem. 1985;31:244–246
  24. Grubbs RD and Maguire ME. Magnesium as a Regulatory Cation: Criteria and Evaluation. Magnesium. 1987;6:113–127
  25. Gupta RK, Gupta P and Moore RD. NMR studies of intracellular metal ions in intact cells and tissues. Annu Rev Biophys Bioeng. 1984;13:221–246
  26. Rouffignac de C, Quamme G. Renal Magnesium Handling and its Hormonal Control. Physiol Rev. 1994;74(2):305–322
  27. Wittner M and Di Stefano A. Effects of antidiuretic hormone, parathyroid hormone and glucagon on the cortical and medullary thick ascending limb of Henle’s loop of the mouse nephron. Pflügers Arch. 1990;415:707–712
  28. Elalouf JM, Roinel N and De Rouffignac C. Stimulation by human calcitonin of electrolyte transport in distal tubules of rat kidney. Pflügers Arch. 1983;399:11–18
  29. Quamme GA, Carney SL, Wong NLM and Dirks JH. Effect of parathyroid hormone on renal calcium and magnesium reabsorption in magnesium deficient rats. Pflügers Arch. 1980;386:59–65
  30. Mavichak V, Wong NLM, Quamme GA, Magil AB, Sutton RAL and Dirks JH. Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kid Int. 1985;28:914–921
  31. Doboyan DC, Levi J, Jacobs C, Kosek J and Weiner MW. Mechanism of cis-Platinum Nephrotoxicity: II. Morphologic Observations. J Pharmacol Exp Ther. 1980;213:551–556
  32. Daugaard G, Abildgaard U, Holstein-Rathlou N-H, Leyssac PP, Amtorp O and Dikhoff TG. Acute effect of cisplatin on renal hemodynamics and tubular function in dog kidneys. Renal Physiol. 1986;9:308–316
  33. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E and Sternberg SS. The Renal Pathology in Clinical Trials of Cis-Platinum (II) Diamminechloride. Cancer. 1977;39:1362–1371
  34. Guinee DG, van Zee B and Houghton DC. Clinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapy. Cancer. 1993;71:4050–4054
  35. Kanaka C, Oetliker OH and Bianchetti MG. Chronic Cisplatin Tubulopathy in Humans and Animals: Clear-Cut Discrepant Findings. Nephron. 1991;59:693
  36. Daugaard G, Abildgaard U, Larsen S. Functional and histopathological changes in dog kidneys after administration of cisplatin. Renal Physiol. 1987;10:54–64
  37. Daugaard G, Abildgaard U, Holstein-Rathlou N-H, Bruunshuus I, Bucher D and Leyssac PP. Renal tubular functions in patients treated with high-dose cisplatin. Clin Pharmacol Ther. 1988;44:164–172
  38. Daugaard G, Strandgaard S, Holstein-Rathlou N-H. The renal handling of sodium and water is not affected by the standard-dose cisplatin treatment for testicular cancer. Scand J Clin Lab Invest. 1987;47:455–459
  39. Bar RS, Wilson HE and Mazzaferri EL. Hypomagnesemic hypocalcemia, secondary to renal magnesium wasting: a possible consequence of high dose gentamicin therapy. Ann Intern Med. 1975;82:646–649
  40. Meyer KB and Madias NE. Cisplatin Nephrotoxicity. Miner Electrolyte Metab. 1994;20:201–213
  41. Daugaard G, Rossing N and Rørth M. Effects of high-dose cisplatin on glomerular function in the human kidney. Cancer Chemother Pharmacol. 1988;21:163–167
  42. Daugaard G. Cisplatin nephrotoxicity: Experimental and clinical studies. Dan Med Bull. 1990;37:1–12
  43. Lam M and Adelstein DJ. Hypomagnesemia and Renal Magnesium Wasting in Patients Treated With Cisplatin. Am J of Kidney Dis. 1986;8:164–169
  44. Ariceta G, Rodriguez-Soriano J, Vallo A and Navajas A. Acute and Chronic Effects of Cisplatin Therapy on Renal Magnesium Homeostasis. Med Pediatr Oncol. 1997;28:35–40
  45. Ashraf M, Scotchel PI, Krall JM and Flink EB. Cisplatinum-induced hypomagnesemia and peripheral neuropathy. Gynecol Oncol. 1983;16:309–318
  46. Schilsky RL and Anderson T. Hypomagnesemia and renal Magnesium Wasting in Patients Receiving Cisplatin. Ann Intern Med. 1979;90:929–931
  47. Buckley JE, Clark VL, Meyer TJ and Pearlman NW. Hypomagnesemia After Cisplatin Combination Chemotherapy. Arch Intern Med. 1984;144:2347–2348
  48. Stewart AF, Keating T and Schwartz PE. Magnesium homeostasis following chemotherapy with cisplatin: A prospective study. Am J Obstet Gynecol. 1985;153:660–665
  49. Mavichak V, Coppin CML, Wong NLM, Dirks JH, Walker V and Sutton RAL. Renal magnesium wasting and hypocalciuria in chronic cis-platinum nephropathy in man. Clin Sci. 1988;75:203–207
  50. Netten PM, de Mulder PHM, Theeuwes AG, Willems JL, Kohler BEM, Wagener DJT. Intravenous magnesium supplementation during cisdiammine-dichloroplatinum administration prevents hypomagnesemia. Ann Oncol. 1990;1:369–372
  51. Willox JC, McAllister EJ, Sangster G and Kaye SB. Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: A randomised trial. Br J Cancer. 1986;54:19–23
  52. Martin M, Diaz-Rubio E, Casado A, Vega JML, Sastre J and Almenarez J. Intravenous and Oral Magnesium Supplementations in the Prophylaxis of Cisplatin-Induced Hypomagnesemia. Am J Clin Oncol. 1992;15(4):348–351
  53. Markman M, Rothman R, Reichman B. Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. J Cancer Res Clin Oncol. 1991;117:89–90
  54. Sjøgren A, Florén CH and Nilsson Å. Magnesium and potassium status in healthy subjects as assessed by analysis of magnesium and potassium in skeletal muscle biopsies and magnesium in mononuclear cells. Magnesium. 1987;6:91–99
  55. Stendig-Lindberg G, Bergstrom J and Hultman E. Hypomagnesaemia and Muscle Electrolytes and Metabolities. Acta Med Scand. 1977;201:273–280
  56. Sartori S, Nielsen I, Tassinari D. Changes in Intracellular Magnesium Concentrations during Cisplatin Chemotherapy. Oncology. 1993;50:230–234
  57. Al-Ghamdi SMG, Cameron EC and Sutton RAL. Magnesium Deficiency: Pathophysiologic and Clinical Overview. Am J Kid Dis. 1994;24(5):737–752
  58. Hashizume N and Mori M. An Analysis of Hypermagnesemia and Hypomagnesemia. Jpn J Med. 1990;29(4):368–372
  59. Elisaf M, Milionis H and Siamopoulos KC. Hypomagnesemic Hypokalemia and Hypocalcemia: Clinical and Laboratory Characteristics. Miner Electrolyte Metab. 1997;23:105–112
  60. Whang R, Hampton EM and Whang DD. Magnesium homeostasis and Clinical Disorders of Magnesium Deficiency. Ann Pharmacother. 1994;28:220–225
  61. Dørup I, Skajaa K and Thybo NK. Oral magnesium supplementation restores the concentrations of magnesium, potassium and sodium-potassium pumps in skeletal muscle of patients receiving diuretic treatment. J Intern Med. 1993;233:117–123
  62. Crook MA. Hypophosphatemia and hypokalemia in patients with hypomagnesemia. Brit J Biomed Sci. 1994;51:24–27
  63. Rude RK. Magnesium Metabolism and Deficiency. Endocrinol Metab Clin North Am. 1993;22(2):377–395
  64. Jensen JBF, Charles P and Sell A. Disturbances in magnesium/calcium metabolism related to cisplatin therapy (in Danish with English abstract). Ugeskr Læger. 1986;148:3374–3375
  65. Hayes FA, Green AA, Casper J, Cornet J and Evans WE. Clinical evaluation of sequentially scheduled cisplatin and VM-26 in neuroblastoma: response to toxicity. Cancer. 1981;48:1715–1718
  66. Maina A, Richiardi G, Danese S, Defabiani E and Giardina G. Symptomatic hypocalcemia and hypomagnesiemia in cisplatinum-based chemotherapy treated patients: case report. Eur J Gynaecol Oncol. 1996;17:281–282
  67. Kingston ME, Al-Sibai MB and Skooge WC. Clinical manifestations of hypomagnesemia. Crit Care Med. 1986;14(11):950–954
  68. Durlach J, Bara M, Guit-Bara A. Relationship between magnesium, cancer and carcinogenic or anticancer metals. Anticancer Res. 1986;6(6):1353–1361
  69. Parsons FM, Edwards GF, Anderson GK. Regression of malignant tumours in magnesium and potassium depletion induced by diet and haemodialysis. Lancet. 1974;243:
  70. Evans TRJ, Harper CL, Beveridge IG, Wastnage R and Mansi JL. A Randomised Study to Determine Whether Routine Intravenous Magnesium Supplements are Necessary in Patients Receiving Cisplatin Chemotherapy with Continuous Infusion 5-Fluorouracil. Eur J Cancer. 1995;31A:174–178
  71. Vokes EE, Mick R, Vogelzang NJ, Geiser R and Douglas F. A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia. Br J Cancer. 1990;62:1015–1017
  72. Macaulay VM, Begent RHJ, Phillips ME and Newlands ES. Prophylaxis against Hypomagnesaemia Induced by cis-Platinum Combination Chemotherapy. Cancer Chemother Pharmacol. 1982;9:179–181
  73. Merouani A, Davidson SA and Schrier RW. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone. Am J Nephrol. 1997;17(1):53–58
  74. Lofts FJ, Evans TRJ, Wastnage R and Mansi JL. Magnesium Supplements with Cisplatin Chemotherapy. Eur J Cancer. 1996;32A(3):556–557

☆ Correspondance to: Henrik Lajer, Brohusgade 13, 2 tv., 2200 Copenhagen N, DK-Denmark.

☆☆ Altura, B. M.Durlach, J.Seelig, M.

PII: S0305-7372(99)90097-X

doi: 10.1053/ctrv.1999.0097

Cancer Treatment Reviews
Volume 25, Issue 1 , Pages 47-58 , February 1999

Article Tools